Etrumadenant
- Generic Name
- Etrumadenant
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22N8O
- CAS Number
- 2239273-34-6
- Unique Ingredient Identifier
- W0ZE0NT8IF
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Radiation: Stereotactic body radiotherapy (SBRT)Drug: Modified FOLFIRINOX
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Gulam Manji
- Target Recruit Count
- 60
- Registration Number
- NCT06048484
- Locations
- 🇺🇸
Northwell Health R.J. Zuckerberg Cancer Center, Lake Success, New York, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
- Conditions
- Oligometastatic Prostate Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Catherine Spina
- Target Recruit Count
- 23
- Registration Number
- NCT05915442
- Locations
- 🇺🇸
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
- Conditions
- Soft Tissue SarcomaSarcoma,Soft TissueSarcomaRecurrent Dedifferentiated LiposarcomaDedifferentiated LiposarcomaUnresectable Dedifferentiated LiposarcomaMetastatic Dedifferentiated Liposarcoma
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT05886634
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
Study of Novel Treatment Combinations in Patients With Lung Cancer
- Conditions
- Lung CancerResectable Non-Small-Cell Lung CancerAdvanced or Metastatic Non-Small-Cell Lung Cancer
- Interventions
- Drug: Domvanalimab (DOM)Drug: Sacituzumab govitecan-hziy (SG)
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 593
- Registration Number
- NCT05633667
- Locations
- 🇬🇧
St. Bartholomew's Hospital,Substudy-01, London, United Kingdom
🇬🇧St. Bartholomew's Hospital,Substudy-02, London, United Kingdom
🇬🇧St. Bartholomew's Hospital,Substudy-03, London, United Kingdom
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
- Conditions
- Urothelial CarcinomaMetastatic Cancer
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05335941
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05277012
- Locations
- 🇺🇸
Investigational Site, Lincoln, Nebraska, United States
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Prostate CancerMetastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05177770
- Locations
- 🇺🇸
START South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸START Mountain Region, Utah Cancer Specialists, West Valley City, Utah, United States
🇨🇦BC Cancer - The Vancouver Centre, Vancouver, British Columbia, Canada
A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05154136
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
- Conditions
- Rectal Cancer
- Interventions
- Radiation: Radiation therapyDrug: FOLFOX regimen
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 43
- Registration Number
- NCT05024097
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York, United States
🇺🇸New York Presbyterian Hospital - Queens, New York, New York, United States
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
- Conditions
- Oral Cavity Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and NeckHypopharynx Squamous Cell CarcinomaOral Cavity CancerOropharynx CancerPharynx CancerHead and Neck CancerOropharynx Squamous Cell CarcinomaLarynx CancerHypopharynx Cancer
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Jennifer Choe
- Registration Number
- NCT04892875
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.